Medicover AB Class B

Medicover AB Class B

23.35
EUR
-0.15
(-0.64%)
0.57EPS
38.14P/E
3.49BMarket Cap
Feb 10Next Earn

Total Valuation

EUR

As of September 30, 2026, Medicover AB Class B carries a market capitalization of 3.49B, placing it among publicly traded companies globally. Its enterprise value stands at 4.68B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.49B
Enterprise Value4.68B

Important Dates

Medicover AB Class B's next confirmed earnings release is scheduled for February 10, 2027.

Earnings Date2/10/2027

Share Statistics

As of September 30, 2026, Medicover AB Class B has 151.97M shares outstanding.

Shares Outstanding151.97M

Valuation Ratios

As of September 30, 2026, Medicover AB Class B trades at a trailing price-to-earnings ratio of 38.14. The price-to-sales ratio is 1.42, and the price-to-book ratio stands at 6.46.

PE Ratio38.14
PS Ratio1.42
PB Ratio6.46
P/TBV Ratio-16.17
P/FCF Ratio17.85
P/OCF Ratio10.21

Enterprise Valuation

As of September 30, 2026, Medicover AB Class B trades at an EV/EBITDA multiple of 11.62 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.91 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 25.67 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Medicover AB Class B trades at an EV/FCF ratio of 19.36, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 4.68B versus a market cap of 3.49B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.91
EV / EBITDA11.62
EV / EBIT25.67
EV / FCF19.36

Financial Position

As of September 30, 2026, Medicover AB Class B maintains a current ratio of 0.75, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 226.27, indicating elevated leverage, while an interest coverage ratio of 6.43 demonstrates adequate ability to service its debt obligations.

Current Ratio0.75
Quick Ratio0.08
Debt / Equity226.27
Debt / EBITDA3.13
Interest Coverage6.43

Financial Efficiency

EUR

These figures cover the twelve months ended September 30, 2026. The company generates approximately 51,783.90 in revenue per employee across its workforce of 47,256.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee51,783.90
Employee Count47,256.00

Taxes

EUR

Over the twelve months ended September 30, 2026, Medicover AB Class B recorded 29.40M in income tax expense. That works out to an effective tax rate of 25.34, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 116.00M, leaving 91.10M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax29.40M
Effective Tax Rate25.34

Stock Price Statistics

EUR

As of the close on November 17, 2026, Medicover AB Class B's stock has gained approximately 8.60% over the past 52 weeks. The 50-day moving average sits at 23.46, while the 200-day moving average is 20.63.

52-Week Price Change8.60%
50-Day Moving Average23.46
200-Day Moving Average20.63

Income Statement

EUR

Over the twelve months ended September 30, 2026, Medicover AB Class B generated 2.45B in revenue and converted that into 91.10M in net income, yielding earnings per share of 0.57. EBITDA reached 403.10M, while operating income came in at 182.40M.

Revenue2.45B
Gross Profit579.20M
Operating Income182.40M
Pretax Income116.00M
Net Income91.10M
EBITDA403.10M
EBIT182.40M
Earnings Per Share (EPS)0.57

Balance Sheet

EUR

As of September 30, 2026, Medicover AB Class B holds 86.00M in cash and equivalents against 1.26B in total debt, resulting in a net debt position of 756.10M. Total book value stands at 539.60M, with working capital of -271.00M providing operational flexibility.

Cash & Cash Equivalents86.00M
Total Debt1.26B
Net Debt756.10M
Equity (Book Value)539.60M
Book Value Per Share3.55
Working Capital-271.00M

Cash Flow

EUR

Medicover AB Class B produced 340.20M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -145.10M in capital expenditures, free cash flow totaled 195.10M - equivalent to 1.29 per share.

Operating Cash Flow340.20M
Capital Expenditures-145.10M
Free Cash Flow195.10M
FCF Per Share1.29

Margins

Over the twelve months ended September 30, 2026, Medicover AB Class B posted a gross margin of 23.67, reflecting its pricing power and cost economics. The operating margin of 7.45 and net profit margin of 3.72 provide insight into operational efficiency.

Gross Margin23.67
Operating Margin7.45
Pretax Margin4.74
Profit Margin3.72
EBITDA Margin16.47

Dividends & Yields

EUR

Over the twelve months ended September 30, 2026, Medicover AB Class B paid dividends of 0.20 per share. The dividend payout ratio of 36.61 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 5.60, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 5.59, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Medicover AB Class B shareholders.

Dividend Per Share0.20
Payout Ratio36.61
Shareholder Yield5.59
FCF Yield5.60

Scores

As of September 30, 2026, Medicover AB Class B has an Altman Z-Score of 2.89, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.89